TRALI: The Transfusion Lung Injury

If you’re like me, TRALI is the transfusion complication that is most frequently misdiagnosed as pulmonary edema and mistreated with Lasix — and the misdiagnosis has real consequences. Diuresis in a patient with TRALI who is already hemodynamically tenuous can cause cardiovascular collapse. On the anesthesiology oral boards, TRALI is a recognition question, a differential question, and a treatment-choice question where getting the TRALI vs. TACO distinction right determines whether your management is correct.

The setup: a patient receiving a blood product transfusion — most commonly plasma (FFP, cryoprecipitate) or platelets — develops acute hypoxia, bilateral pulmonary infiltrates on CXR, and fever within 6 hours of the transfusion. The question is whether this is inflammatory lung injury (TRALI) or volume overload (TACO).

The Core Logic

TRALI — Transfusion-Related Acute Lung Injury — is an immune-mediated reaction. The donor blood product contains HLA antibodies or anti-granulocyte antibodies (most commonly from previously pregnant female donors who developed antibodies from fetal-maternal HLA sensitization). These antibodies activate the recipient’s neutrophils, which aggregate in the pulmonary microvasculature and release inflammatory mediators — causing capillary leak and non-cardiogenic pulmonary edema. The pathophysiology is essentially ARDS triggered by an antibody reaction.

TACO — Transfusion-Associated Circulatory Overload — is a volume problem. The patient receives too much intravascular volume too quickly, overwhelms the left heart’s ability to accommodate the preload, and develops hydrostatic (cardiogenic) pulmonary edema. The mechanism is identical to acute decompensated heart failure from volume overload.

Clinical distinction: TRALI is non-cardiogenic — no elevation in BNP or PCWP, no jugular venous distension, no improvement with diuretics. TACO is cardiogenic — elevated BNP, elevated PCWP, JVD, and responds to diuretics. Fever is more associated with TRALI. TRALI is the number one cause of transfusion-related mortality. Treatment is supportive — lung-protective ventilation, fluid balance, vasopressors if hypotensive. The offending donor’s blood products should be quarantined and the blood bank notified.

How the Examiner Tests This

Classic scenario: a 50-year-old is receiving FFP for coagulopathy following massive transfusion. One hour after the FFP infusion starts, SpO2 drops to 88%, the chest X-ray shows bilateral infiltrates, and the patient has a temperature of 38.6°C. "What is your diagnosis and management?" TRALI — new hypoxia plus bilateral infiltrates within 6 hours of transfusion plus fever in the absence of preexisting cardiac disease. Stop the transfusion. Notify the blood bank. Provide supplemental oxygen or ventilatory support. Do not aggressively diurese.

Differential probe: "The patient’s BNP comes back at 1200 pg/mL and they have JVD. Does this change your diagnosis?" This points more toward TACO. BNP elevation and signs of elevated venous pressure support a cardiogenic mechanism. Management shifts: cautious diuresis (furosemide 20-40 mg IV), optimization of volume balance. However, the timing and bilateral infiltrates mean TRALI remains on the differential — the two conditions can coexist.

The Board Trap

The aggressive diuresis trap: giving Lasix to "treat the pulmonary edema" without distinguishing TRALI from TACO. In TRALI, the pulmonary edema is not from volume overload — it is from capillary leak. The intravascular volume may be low or normal. Aggressive diuresis causes hemodynamic instability and worsens organ perfusion without improving the lung injury. Lung-protective ventilation and vasopressor support are the cornerstones of TRALI management, not diuretics.

The "continue the blood product" trap: continuing the transfusion or ordering additional products from the same donor while investigating. The transfusion should stop immediately when TRALI is suspected. All products from that donor should be quarantined by the blood bank, and the donor should be investigated for HLA antibodies.

Lead-In Phrases

• "New hypoxia plus bilateral pulmonary infiltrates within 6 hours of a blood product transfusion is TRALI until proven otherwise — I will stop the transfusion immediately and notify the blood bank."
• "I will not aggressively diurese a TRALI patient — the mechanism is non-cardiogenic capillary leak, not volume overload. Diuretics may cause hemodynamic collapse in an already compromised patient."
• "My treatment is supportive: lung-protective ventilation (low tidal volume 6 mL/kg, appropriate PEEP), hemodynamic support with vasopressors if needed, and careful fluid balance."
• "I distinguish TRALI from TACO by clinical context (fever, absence of JVD, normal or low BNP in TRALI versus elevated BNP and JVD in TACO) and by response to treatment — TACO improves with diuretics, TRALI does not."
• "I will document the reaction in the medical record, complete a transfusion reaction report with the blood bank, and ensure the implicated blood product units are quarantined for investigation."

FAQs

What blood products are most commonly implicated in TRALI?

FFP and pooled platelets have the highest risk because they contain the most plasma volume — and therefore the most antibodies from potentially sensitized donors. Packed red blood cells (pRBCs) contain less plasma and have lower TRALI risk, though they can still cause it. Washing red cells reduces the plasma content and may reduce TRALI risk in high-risk patients. The blood banking practice of preferring male donor plasma (less HLA sensitization) has significantly reduced TRALI incidence.

Can TRALI occur with non-blood products?

True TRALI, by definition, requires a blood product transfusion. ARDS from other inflammatory causes can mimic the clinical picture, but the temporal relationship to transfusion (within 6 hours) and the bilateral infiltrates are the defining features of TRALI. TRALI must be distinguished from pre-existing lung injury that was present before transfusion — if the patient had documented bilateral infiltrates before the transfusion, the new hypoxia is not TRALI.

What is the prognosis for TRALI?

Better than classic ARDS. The inflammatory insult in TRALI is typically self-limited — once the offending antibodies are cleared and the neutrophil activation resolves, the capillary leak resolves. Most TRALI patients improve within 24-96 hours with supportive care. Mortality, while significant (5-10% in severe cases), is lower than ARDS from other causes. Patients who require mechanical ventilation generally can be extubated within 72 hours if their underlying condition is otherwise stable.

TRALI is the most deadly transfusion complication, and the most treatable once recognized. The critical distinction from TACO determines whether you diurese or support. Practice the TRALI vs. TACO differential and the lung-protective management strategy in Boards Bot until the distinction is immediate.